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It is reported that diﬀerent microRNA (miRNA) proﬁles can be detected in the blood of cancer patients. We investigated that
whether the key serum miRNAs could discriminate patients with and without breast cancer. This study was divided into three
parts: (1) miRNA marker discovery using SOLiD sequencing-based miRNA proﬁling on cancerous and adjacent noncancerous
breast tissue of one breast cancer patient; (2) marker selection and validation by real-time PCR on a small set of serum; (3) gene
ontology analysis of the key miRNA target genes. Of genome-wide tissue miRNA expression analysis, ﬁve miRNAs were found to
be altered more than ﬁvefold by SOLiD sequencing (i.e., miR-29a,miR-23a, miR-23b, miR-192, and miR-21). All the ﬁve miRNAs
were validated on the 20 breast cancer patients and 20 controls. miR-29a and miR-21 were signiﬁcantly increased in the serum
of breast cancer patients (P<. 05). Gene ontology analysis of the target genes revealed enrichment for special biological process
categories, that is, signaltransduction, development, apoptosis,cell proliferation,and cell adhesion. SOLiDsequencing provides a
promising method for cancer-related miRNA proﬁling. Serum miRNAs may be useful biomarkers for breast cancer detection.
1.Introduction
Recently, microRNAs (miRNAs), small noncoding RNAs of
∼22 nucleotides (nt) in length, have been implicated in
several carcinogenic processes by acting either as tumor
suppressors or oncogenes. Studies have shown that miRNAs
expression proﬁles can classify human cancers [1–7]. Fur-
thermore, some reports also suggest that cell-free circulating
m i R N A se x i s t e di ns e r u ma n dp l a s m a[ 8–14]. While cancer-
speciﬁc miRNAs are important for the molecular basis of
cancer, blood-based miRNAs as biomarkers could be more
vital for early detection, diagnosis, and followup of cancer
patients. Earlier work by comparing circulating miRNAs
expression in diﬀuse large B-cell lymphoma (DLBCL)
patients with healthy controls found that cancer can aﬀect
serummiRNAlevels[8].Later,Mitchell etal.screenedmulti-
plemiRNAbiomarkercandidates(miR-100,miR-125b,miR-
141, miR-143, miR-205, and miR-296) in serum collected
from 25 individuals with metastatic prostate cancer and 25
healthyage-matchedmalecontrolindividualsandfoundthat
in the sera of human metastatic prostate cancer patients,
m i R - 1 4 1w a sv e r yh i g h l yo v e r e x p r e s s e da n dm o d e r a t e l y
correlated with prostate-speciﬁc antigen (PSA) level. The
data showed that miR-141 levels could identify prostate
cancer patients with high sensitivity and perfect accuracy
[10]. Chen et al. employed the Solexa approach to sequence
serum miRNA proﬁling of patients with nonsmall cell lung
carcinoma (NSCLC). Compared with health subjects, 28
miRNAs were missing and 63 new miRNAs were detected
in the lung cancer patients. More speciﬁcally, this study
determined that miR-25 and miR-223 were highly expressed
in lung cancer sera [12]. Ng et al. investigated whether
plasma miRNAs could discriminate patients with and with-
out colorectal cancer (CRC). Of the panel of 95 miRNAs
analyzed by real-time PCR-based miRNA proﬁling, miR-
92 diﬀerentiated CRC from gastric cancer, inﬂammatory2 Journal of Biomedicine and Biotechnology
bowel disease (IBD), and normal subjects, suggesting that
miR-92 can be a potential noninvasive molecular marker
for CRC screening [14]. Accordingly, it raises the possibility
of using circulating miRNAs as novel blood-based molec-
ular markers for cancer detection. In this study, we used
a strategy of genome-wide screening by Applied Biosystem’s
next-generation sequencing system which is sequencing by
oligonucleotide ligation and detection (SOLiD) to analyze
the diﬀerent genome-wide miRNA expression proﬁling in
breast cancer. Our hypothesis is that some key miRNAs are
detectable in both serum and breast cancer biopsies, which
may be useful for breast cancer detection.
2.PatientsandMethods
2.1. Patient Samples. In part one (miRNA screening),
miRNA proﬁles were generated from cancerous and adjacent
noncancerous breast tissue from one patient by SOLiD
sequencing. Two diﬀerential miRNA expression patterns
were established. By comparing the genome-wide miRNA
expressionfromcancerousandadjacent noncancerousbreast
tissue,upregulatedmiRNAsinbreastcancertissuewereiden-
tiﬁed for further analysis in part two.
In part two (selection and validation of key miRNAs),
serumwascollectedfromagroupof20breastcancerpatients
before undergoing operation and 20 age-matched controls,
respectively. The selected miRNAs must be signiﬁcantly
elevated in 20 breast cancer patients.
Informed consent was obtained from participants for the
use of blood and tissue samples in this study. This project
was approved by Southeast University and Nanjing Medical
University Clinical Research Ethics Committee, Nanjing,
China. No patients received chemotherapy or radiotherapy
before tissue and blood collection.
2.2. Samples Processing and RNA Extraction. Tumor tissues
were crashed into powders with liquid nitrogen, and imme-
diately RNA (
￿200nt) was extracted using mirVana miRNA
IsolationKit(Ambion)followingthemanufacturer’s instruc-
tion. The whole blood was centrifuged at 1600rpm for
5min, and serum was transferred into new tubesfollowed by
further centrifugation at12000rpmfor 10min tocompletely
remove cell debris. Total RNA containing small RNA was
extracted from 500μl of serum using Trizol LS reagent
(Invitrogen) and miRNeasy Mini Kit (Qiagen) according to
N gE K ’ sm o d i ﬁ e dm e t h o d[ 14].
2.3. MicroRNA Proﬁling by SOLiD Sequencing. Libraries for
SOLiD sequencing were prepared according to the manufac-
turer’s protocol (Small RNA Expression Kit, Applied Biosys-
tems). Brieﬂy, miRNA samples (100ng) were hybridized
and ligated overnight with adapter mix, reverse transcribed,
RNase H-treated, and PCR ampliﬁed. And PCR products
were cleanupandselected onagarose gelsbysize 105–150bp.
Template bead preparation, emulsion PCR, and deposition
were performed using the SOLiD V2 sequencing system
(Applied Biosystems) at the State Key Lab of Bioelectronics
Laboratory, Southeast University of China.
2.4. Sequence Analysis. Mapping of SOLiD reads was ana-
lyzed by SOLiD system small RNA analysis pipeline tool
(RNA2MAP). Firstly, alignment of three mismatches in the
maximum length (18nt) was identiﬁed, indicating initial
seeds locations. And less than 6 mismatches were allowed
in full-length mapping. To increase signal quality, those
alignments beads reaching a minimum of 5 times in any of
the libraries were conservatively selected. After calculating
length distribution and ﬁltrating by rRNA, tRNA, snRNA,
and snoRNA, reads were mapped with miRBase (release
15.0 at http://microRNA.sanger.ac.uk/), and the total copy
number of each sample was normalized to 100000. Mann-
Whitney test was used to determine the statistical signiﬁ-
cance of diﬀerences expression levels between breast cancer
tissue and normal adjacent breast tissue. Fold change was
calculated based on the normalized counts. A candidate that
passes thethreecriteria istakenas aputativemiRNA:(1)fold
change >5, (2) at least 5 copies by SOLiD sequencing.
2.5. MicroRNAs Quantiﬁcation by Real-Time PCR. Micro-
RNA quantiﬁcation was performed by SYBR green qRT-
PCR assay. In brief, serum RNA containing miRNA was
polyadenylated by poly (A) polymerase and reverse tran-
scribed to cDNA using miScript reverse transcription kit
(Qiagen) according to the manufacturer’s instructions. Real-
time qPCR was performed using miScript SYBR Green
PCR kit (Qiagen) with the manufacturer-provided miS-
cript universal primer and the miRNA-speciﬁc forward
primers in ABI PRISM 7300 real-time PCR system (Applied
Biosystems). The cycle threshold (Ct) is deﬁned as the
number of cycles required for the ﬂuorescent signal to
cross the threshold in qPCR. ΔCt = Ct(miRNA)− Ct(RNU6B).
ΔΔCt = ΔCt(case) − ΔCt(control). Fold change of gene was
calculated by the equation 2−ΔΔCt [15]. The miRNA-speciﬁc
primer sequences were 5 -ACGCAAATTCGTGAAGCGTT-
3  for RNU6B; other primer sequences were designed based
on the miRNA sequences obtained from the miRBase
database (http://microrna.sanger.ac.uk/). Each reaction was
performed in a ﬁnal volume of 20μl containing 2μlo ft h e
cDNA, 10μlo f2 × SYBR Green PCR Master mix, of 2μl
and 10× miScript universal primer and 10× miScript primer
assay. The ampliﬁcation proﬁle was denaturation at 95◦C,
15min, followed by 40 cycles of 94◦C, 15s; 55◦C, 30s, and
70◦C, 34s. Each sample was run in duplicates for analysis.
2.6. Target Prediction and GO Analysis. Predicted targets of
miRNAs diﬀerentially expressed in this study were deter-
mined using mRBase targets (http://www.mirbase.org/ and
http://pictar.mdc-berlin.de/). In addition, we used Capital-
Bio Molecule Annotation System V3.0 to perform gene
ontology (GO) analysis on the target genes and speciﬁc
biological process categories were enriched.
2.7. Statistical Analysis. The signiﬁcance of serum miRNA
levels was determined by Mann-Whitney, Kruskal-Wallis, or
χ2 testwhichwassuitable.AllPvaluesweretwosidedandless
than .05 was considered statistically signiﬁcant. All statistical
calculations were performed by the SPSS software (versionJournal of Biomedicine and Biotechnology 3
16.0) and GraphPad Prism 5 Demo software (GraphPad
software, San Diego, Calif, USA).
3.Results
3.1. Patients. Twenty-one breast cancer patients (BC) and
20 controls (C) were included in the study. There were no
signiﬁcant diﬀerences of age among BC patients (53 ± 4.5
years)andcontrols(51±6.9years)(P = .87,ANOVA).TNM
stage of the patient in part one was II. The number of every
TNM stage of subjects in part two was 5 for stage I, 5 for
II, 5 for III, and 5 for IV, respectively. Tumors were staged
according to the tumor node—metastasis for breast cancer,
AJCC (American Joint Committee on Cancer), 7th edition.
3.2. SOLiD Sequencing of miRNAs from Cancerous and Adja-
cent Noncancerous Breast Tissue. In this key miRNA screen-
ing step, SOLiD sequencing-based miRNA expression proﬁl-
ingwasperformed toidentifydiﬀerentialexpressionpatterns
of miRNAs from cancerous and adjacent noncancerous
breast tissue. 560,054 eﬀective reads were obtained in
cancerous tissue and 3,300,900 eﬀective reads adjacent
noncancerous tissue. After ﬁltrated by rRNA, tRNA, snRNA,
and snoRNA, the remaining eﬀective reads were mapped to
miRNAPrecursorLibrary-Human. 41,225and203,889reads
were obtained from cancerous and adjacent noncancerous
tissue, respectively. In these reads, the most abundant length
was 22nt size class in both of cancerous and adjacent
noncancerous tissue. The percentage was 29.8% and 23.4%,
respectively (Figure 1).ComparedtothemiRBase(15.0),546
precursormiRNAout of940 knownprecursor miRNAswere
identiﬁed in cancerous tissue, and 364 precursor miRNAs
in adjacent noncancerous tissue. To study the diﬀerential
expression proﬁle of genome-wide tissue miRNAs between
cancerous and adjacent noncancerous breast tissue, Mann-
Whitney test and fold change of sequenced miRNAs were
employed.Using2-foldexpressiondiﬀerenceasacutoﬀlevel,
19 upregulated miRNAs were identiﬁed (Table 1). Among 19
upregulated miRNAs, ﬁve miRNAs were found to be altered
morethan ﬁvefoldbySOLiDsequencing(i.e.,miR-29a, miR-
23a, miR-23b, miR-192, and miR-21), and could be selected
as candidates.
3.3. Validation of Key miRNAs in Serum of Breast Cancer
Patients. To validate the putative markers identiﬁed from
part one, real-time PCR assays were developed to quantify
miRNAs in serum. Using RNU6B as normalization control,
expression levels of the marker miRNAs (miR-29a, miR-
23a, miR-23b, miR-192, and miR-21) were assessed by real-
time PCR on the 40 serum samples including 20 breast
patients and 20 controls. Our data indicated that miR-
29a and miR-21 were signiﬁcantly elevated in serum of
breast cancer patients than those in controls (P<. 001,
Mann-Whitney test, Figures 2(a) and 2(b)). Spearman rank
correlation showed that serum levelsof miR-29a and miR-21
were not correlated (R2 = 0.298, P = .202, Figure 3), and
we examined whether the serum miR-29a and miR-21 level
may be associated with stages of cancer. The patients were
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Figure 1: Length distribution of sequenced miRNAs.
Table 1: Upregulated miRNAs (change >2f o l da sac u t o ﬀ level) in













hsa-miR-29a 737 11 10.41
hsa-miR-23a 278 5 8.64
hsa-miR-192 452 9 7.80
hsa-miR-23b 200 5 6.21
hsa-miR-21 1228 37 5.15
hsa-miR-222 183 6 4.74
hsa-miR-761 264 9 4.55
hsa-miR-223 298 11 4.21
hsa-miR-1308 3347 132 3.94
hsa-miR-532-5p 138 6 3.57
hsa-miR-130b 370 20 2.87
hsa-miR-4315 301 17 2.75
hsa-miR-4308 86 5 2.67
hsa-miR-24 540 32 2.62
hsa-miR-125a-5p 79 5 2.45
hsa-miR-150 72 5 2.23
hsa-let-7f 222 16 2.15
hsa-let-7i 69 5 2.14
hsa-miR-103 1786 137 2.02
stratiﬁed by TNM staging of the 20 breast cancer patients.
The results indicated that miR-29a (P = .86) and miR-
21 (P = .50) levels were not diﬀerent among the staging
(Kruskal-Wallis test, Figure 4), but statistically signiﬁcant
diﬀerences of miR-29a were obtained as individual tumor
stagewas comparedwiththecontrols(stageI, P = .002;stage4 Journal of Biomedicine and Biotechnology
II, P = .004; stage III, P = .004; stage IV, P = .01, Mann-
Whitney test).
3.4. Gene Ontology Analysis. Each of miR-29a and miR-21
has a broad range of predicted target genes (Table 2). Target
genes predicted by mRBase targets for all assayed miRNAs
were used as reference. Furthermore, we performed GO
analysis on the target genes of these miRNAs and found
that speciﬁc biological process categories were enriched,
such as signal transduction, development, apoptosis, cell
proliferation, cell adhesion, and (Table 3).
4.Discussion
This is the ﬁrst report on genome-wide miRNA expression
proﬁle of breast cancer patient by SOLiD sequencing. We
found ﬁve miRNAs to be altered more than ﬁvefold by
SOLiD sequencing, and two miRNAs, miR-29a and miR-
21, were identiﬁed as signiﬁcantly increased in the serum of
breast cancer patients. These key miRNAs, if validated in
a large set of serum samples, may serve as noninvasive
markers for breast cancer detection. In addition, miRNAs
are very stable in plasma and serum, which are protected
from RNases and remain stable even in harsh conditions
[10, 12]. Therefore, their stability makes miRNA expression
well suited for being tested in samples. And because of the
simplicityandreproducibilityofgettingbloodsamples,these
noninvasive and easily detectable biomarkers may have a
great potential in cancer therapy and prognosis.
A full understanding of miRNA expression proﬁles as
potential biomarkers for diagnosis and prognosis is neces-
sary. About the two key miRNAs, miR-21 has been exten-
sivelyevaluatedintheliterature.ThemiR-21isoverexpressed
in a wide variety of cancers and has been causally linked
to cellular proliferation, apoptosis, and migration. Si et al.
[16] transfected breast cancer MCF-7 cells with anti-miR-
21 oligonucleotides and found that anti-miR-21 suppressed
both cell growth in vitro and tumor growth in the xenograft
mouse model, associated with increased apoptosis and
decreased cell proliferation, which could be in part owing
to the downregulation of the antiapoptotic Bcl-2. Zhu et al.
[17] found that suppression of miR-21 in metastatic breast
cancer MDA-MB-231 cells signiﬁcantly reduced invasion
and lung metastasis. Several potential target genes directly
regulated by miR-21 have been identiﬁed, including the
tumor suppressor tropomyosin 1 (TPM1) [18]a n dt h e
protein-programmedcelldeath4(PDCD4)[19,20]inbr east
cancer cells. As for miR-29a, the overexpression of miR-
29a suppressed the expression of tristetraprolin (TTP), a
protein involved in the degradation of messenger RNAs with
AU-rich 3 -untranslated regions, and led to epithelial-to-
mesenchymal transition (EMT) and metastasis in cooper-
ation with oncogenic Ras signaling [21]. Interestingly, one
of the predicted target genes of miR-29a is PTEN, which
is a previously identiﬁed target of miR-21 in heptocellular
carcinoma, suggesting that cell and tissue type-speciﬁc
diﬀerences might result in diﬀerent functional miR targets
[22]. Further investigation of regulatory mechanism of these
miRNAs and their targets may improve our understanding
of molecular pathogenesis of breast cancer as well as therapy
and prognosis.
Notably, we demonstrated that SOLiD sequencing can
provide a more accurate screen method for genome-wide
miRNA proﬁle of breast cancer. This is a recent introduction
of deep sequencing technology, enabling the simultaneous
sequencing of up to millions of DNA or RNA molecules,
and providing a promising option for proﬁling miRNAs.
Deep sequencing overcomes many of the disadvantages
of microarrays, which suﬀer from background and cross-
hybridization problems and measure only the relative abun-
dances of previously discovered miRNAs. Deep sequencing
measures absolute abundance (over a wider dynamic range
than possible with microarrays) and is not limited by array
content, allowing for the discovery of novel miRNAs or
othersmall RNAspecies. A number of othernext-generation
sequencing technologies are currently in widespread use,
including pyrosequencing (454 sequencing, Roche), which
providesupto400,000sequencesofupto250ntinlengthfor
a single read, and Illumina/Solexa and AB SOLiD generate
shorter reads (35bp) but generate >1Gbpofsequencedata
per run. Chen et al. sequenced all serum miRNAs of healthy
Chinese subjects employing Solexa and found over 100 and
91 serum miRNAs in male and female subjects, respectively.
And further studies revealed that serum miRNAs contain
ﬁngerprints for various diseases, such as lung cancer, col-
orectal cancer, and diabetes [12]. Hu et al. also used Solexa
sequencing to test diﬀerent serum-miRNA expression proﬁle
between patients suﬀering from non-small-cell lung cancer
(NSCLC) with longer survival and short survival. Levels
of four miRNAs (i.e., miR-486, miR-30d, miR-1, and miR-
499) were signiﬁcantly associated with overall survival [23].
In addition, Qi et al. [24] analyzed the miRNA expression
proﬁles from adenovirus type 3 (AD3) infected Human
laryngeal epithelial (Hep2) cells, and Schulte et al. [25]
revealed diﬀerential expression of microRNAs in favorable
versus unfavorable neuroblastoma using SOLiD sequencing,
respectively. This strategy of deep sequencing provides a
powerful approach thatallowsrapididentiﬁcationofmiRNA
expression proﬁle, of course, which should be evaluated
using independent validation methods, for example, RT-
qPCR.
In recent research, Zhu et al. analyzed miR-16, miR-
145, and miR-155 in archived serum specimens from 13
subjects with breast cancer and 8 subjects without. The
results showed that miR-155 may be diﬀerently expressed in
the serum of women with progesterone receptor positive
tumors compared to those were negative [26]. In another
study, Wang et al. examined 6 miRNAs (miRNA-21, 106a,
126, 155, 199a, and 335) in the serum from 68 patients
with breast tumors and 40 healthy subjects. They found
that the expression ofmiR-21, miR-126, miR-155, miR-199a,
and miR-335 was closely associated with clinicopathologic
features of breast cancer (P<. 05), such as histological
tumor grades and sex hormone receptor expression [27].
Compared with the above research, our studies have some
advantages: (1) genome-wide miRNA expression analysis by

















































































Figure 2: Scatter plot of serum levels of (a) miR-29a and (b) miR-21 in controls (C, n = 20) and breast cancer patients (BC, n = 20).
ExpressionlevelofmiRNAswasnormalizedtoRUNB6.Thelinerepresents themeanvalue.Statisticallysigniﬁcantdiﬀerence wasdetermined
by Mann-Whitney test with GraphPad Prism 5 Demo software.
Table 2: Diﬀerentially expressed miRNAs and predicted target genes.
miRNA Chromosomallocation Predicted target genes∗
hsa-miR-29a 7q32.3 PTEN, AKT3, CDK6, FRAG1, MARK3, PCTK1, PRKG1, PRKG1, SGK, SLK
hsa-miR-21 17q23.1 PDCD4, BCL2, PTEN, CREBL2, JAK1, SKI, PITX2, PLAG1, STAT3, E2F3
∗Part of the predicted target genes from http://www.mirbase.org/ and http://pictar.mdc-berlin.de/.

























Figure 3: Scatter plot of expression level correlation between miR-
29a and miR-21 in controls (C, n = 20) and breast cancer patients
(BC, n = 20). Correlation was obtained by Spearman correlation,
R2 = 0.298, P = .202.
selected and validated by two steps. Butthere are several lim-
itations in our studies: (1) serum-miRNA proﬁling should
be analyzed and compared with tissue-miRNA proﬁling to
identify coregulated miRNAs; (2) the sample size we used
is too small, further validation of key miRNAs in large
scale subjects is necessary; (3) despite of the signiﬁcant
increasing of miR-29a and miR-21 in the serum of breast
cancer patients, it is desirable to identify the correlation with
speciﬁcbreastcancerbiopathologicfeatures,suchasestrogen
and progesterone receptor expression, vascular invasion, or
Table 3: The results of gene ontology analysis targets of diﬀeren-
tially expressed miRNAs.





GO:0006350 transcription 36 23
GO:0006468 protein amino acid
phosphorylation 11 5
GO:0006810 transport 11 3
GO:0006915 apoptosis 8 1
GO:0007049 cell cycle 9 7
GO:0007155 cell adhesion 27 3
GO:0007156 homophiliccell adhesion 14 1
GO:0007165 signal transduction 19 14
GO:0007242 intracellular signalingcascade 2 2
GO:0007267 cell-cell signaling 2 3
GO:0007275 development 22 10
GO:0008152 metabolism 3 4
GO:0008283 cell proliferation 2 3
GO:0008380 RNA splicing 3 3
GO:0016568 chromatin modiﬁcation 6 5
GO:0030154 cell diﬀerentiation 11 5
Values expressed as the number of genes targeted by miRNA.
proliferation index. If further validationcan be performed, it
would add more value to use these markers for breast cancer



















































































Figure 4: Box plot of serum (a) miR-29a and (b) miR-21 level across stage. Expression levels of the miRNAs were normalized to RUN6B.
The box represents the interquartile range, and the line across the box indicated the median value. Statistically signiﬁcant diﬀerences were
determined by Mann-Whitney test.
5.Conclusion
Our studies were beneﬁcial from SOLiD sequencing for
genome-wide miRNA expression proﬁle followed by qRT-
PCR validation. This novel application provides an impor-
tant advancement in miRNA detection and proﬁling and has
the capacity to dramatically advance our understanding of
the role for miRNAs in disease pathogenesis.
ConﬂictofInterests
The authors declare that they have no conﬂict of interests.
Acknowledgment
This work was supported by Q. Y. Ge, from the National
Natural ScienceFoundationof China (Grant no. 60701008).
References
[1] J. Lu, G. Getz, E. A. Miska et al., “MicroRNA expression pro-
ﬁles classify human cancers,” Nature, vol. 435, no. 7043, pp.
834–838, 2005.
[ 2 ]R .I .G r e g o r ya n dR .S h i e k h a t t a r ,“ M i c r o R N Ab i o g e n e s i sa n d
cancer,” Cancer Research, vol. 65, no. 9, pp. 3509–3512, 2005.
[3] G.A.CalinandC.M.Croce, “MicroRNA signaturesinhuman
cancers,” Nature Reviews Cancer, vol. 6, no. 11, pp. 857–866,
2006.
[4] S. Volinia, G. A. Calin, C. G. Liu et al., “A microRNA expres-
sion signature of human solid tumors deﬁnes cancer gene
targets,” Proceedings of the National Academy of Sciences of the
United States of America, vol. 103, no. 7, pp. 2257–2261, 2006.
[5] M.EderandM.Scherr,“MicroRNAandlungcancer,”TheNew
England Journal of Medicine, vol. 352, no. 23, pp. 2446–2448,
2005.
[ 6 ]S .R o e s s l e r ,A .B u d h u ,a n dX .W .W a n g ,“ F u t u r eo fm o l e c u l a r
proﬁling of human hepatocellular carcinoma,” Future Oncol-
ogy, vol. 3, no. 4, pp. 429–439, 2007.
[7] M.V.Iorio,R.Visone,G.DiLevaetal.,“MicroRNAsignatures
in humanovarian cancer,” Cancer Research,vol.67, no.18,pp.
8699–8707, 2007.
[8] C. H. Lawrie, S. Gal, H. M. Dunlop et al., “Detection of
elevated levels of tumour-associated microRNAs in serum of
patients with diﬀuse largeB-cell lymphoma,”British Journal of
Haematology, vol. 141, no. 5, pp. 672–675, 2008.
[9] S. S. Chim, T. K. Shing, E. C. Hung et al., “Detection and
characterization of placental microRNAs in maternalplasma,”
Clinical Chemistry, vol. 54, no. 3, pp. 482–490, 2008.
[ 1 0 ]P .S .M i t c h e l l ,R .K .P a r k i n ,E .M .K r o he ta l . ,“ C i r c u l a t i n g
microRNAs as stable blood-based markers for cancer detec-
tion,” Proceedings of the National Academy of Sciences of the
United States of America, vol. 105, no. 30, pp. 10513–10518,
2008.
[11] S. Gilad, E. Meiri, Y. Yogev et al., “Serum microRNAs are
promising novel biomarkers,” PLoS ONE,v o l .3 ,n o .9 ,A r t i c l e
ID e3148, 2008.
[12] X.Chen,Y.Ba,L.Maetal.,“CharacterizationofmicroRNAsin
serum: a novel class of biomarkers for diagnosis of cancer and
other diseases,” Cell Research, vol. 18, no. 10, pp. 997–1006,
2008.
[13] D. D. Taylor and C. Gercel-Taylor, “MicroRNA signatures of
tumor-derived exosomes as diagnostic biomarkers of ovarian
cancer,” Gynecologic Oncology, vol.110,no.1,pp. 13–21,2008.
[ 1 4 ]E .K .N g ,W .W .C h o n g ,H .J i ne ta l . ,“ D i ﬀerential expression
of microRNAs in plasma of patients with colorectal cancer: a
potential marker for colorectal cancer screening,” Gut, vol. 58,
no. 10, pp. 1375–1381, 2009.
[15] K. J. Livak and T. D. Schmittgen, “Analysis of relative gene
expression data using real-time quantitative PCR and the
2−ΔΔCT Method,” Methods,vol. 25, no. 4, pp. 402–408, 2001.Journal of Biomedicine and Biotechnology 7
[ 1 6 ]M .L .S i ,S .Z h u ,H .W u ,Z .L u ,F .W u ,a n dY .Y .M o ,“ m i R - 2 1 -
mediated tumor growth,” Oncogene, vol. 26, no. 19, pp. 2799–
2803, 2007.
[17] S. Zhu, H. Wu, F. Wu, D. Nie, S. Sheng, and Y. Y. Mo,
“MicroRNA-21 targets tumor suppressor genes in invasion
and metastasis,” Cell Research, vol. 18, no. 3, pp. 350–359,
2008.
[18] S. Zhu, M. L. Si, H. Wu, and Y. Y. Mo, “MicroRNA-21 targets
thetumorsuppressorgenetropomyosin1(TPM1),”Journal of
Biological Chemistry, vol. 282, no. 19, pp. 14328–14336, 2007.
[19] Z. Lu, M. Liu, V. Stribinskis et al., “MicroRNA-21 promotes
cell transformation by targeting the programmed cell death 4
gene,” Oncogene, vol. 27, no. 31, pp. 4373–4379, 2008.
[20] L. B. Frankel, N. R. Christoﬀersen, A. Jacobsen, M. Lindow,A.
K r o g h ,a n dA .H .L u n d ,“ P r o g r a m m e dc e l ld e a t h4( P D C D 4 )
is an important functional target of the microRNA miR-21 in
breast cancer cells,” J o u r n a lo fB i o l o g i c a lC h e m i s t r y , vol. 283,
no. 2, pp. 1026–1033, 2008.
[21] C. A. Gebeshuber, K. Zatloukal, and J. Martinez, “miR-29a
suppresses tristetraprolin, which is a regulator of epithelial
polarity and metastasis,” EMBO Reports,v o l .1 0 ,n o .4 ,p p .
400–405, 2009.
[22] F. Meng, R. Henson, H. Wehbe-Janek, K. Ghoshal, S. T.
Jacob, and T. Patel, “MicroRNA-21 regulates expression of
the PTEN tumor suppressor gene in human hepatocellular
cancer,” Gastroenterology, vol. 133, no. 2, pp. 647–658, 2007.
[23] Z. Hu, X. Chen, Y. Zhao et al., “Serum microRNA signatures
identiﬁedinagenome-wideserummicroRNAexpressionpro-
ﬁlingpredict survivalofnon-small-celllungcancer,”Journal of
Clinical Oncology, vol. 28, no. 10, pp. 1721–1726, 2010.
[ 2 4 ]Y .Q i ,J .T u ,L .C u ie ta l . ,“ H i g h - t h r o u g h p u ts e q u e n c i n go f
microRNAs in adenovirus type 3 infected human laryngeal
epithelial cells,” Journal of Biomedicine and Biotechnology,v o l .
2010, Article ID 915980, 2010.
[25] J. H. Schulte, T. Marschall, M. Martin et al., “Deep sequencing
reveals diﬀerential expression of microRNAs in favorable
versus unfavorable neuroblastoma,” Nucleic Acids Research,
vol. 38, no. 17, pp. 5919–5928, 2010.
[26] W. Zhu, W. Qin, U. Atasoy, and E. R. Sauter, “Circulating
microRNAs in breast cancer and healthy subjects,” BMC Re-
search Notes, vol. 2, Article ID 89, 2009.
[27] F. Wang, Z. Zheng, J. Guo, and X. Ding, “Correlation and
quantitation of microRNA aberrant expression in tissues and
sera from patients with breast tumor,” Gynecologic Oncology,
vol. 119, no. 3, pp. 586–593, 2010.